The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Feature|Articles|January 30, 2026
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
Author(s)Kyle Doherty
Fact checked by: Chris Ryan
OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.
Advertisement
Advertisement
Over the course of 2025, clinical trial data presented during major medical meetings across lung and gynecologic cancers, as well as hematologic malignancies, made major waves. Notable advances included the emergence of relacorilant (CORT125134) in platinum-resistant ovarian cancer (PROC), the confirmation of the role of tarlatamab-dlle (Imdelltra) in extensive-stage small cell lung cancer (ES-SCLC), and event-free survival (EFS) improvement with venetoclax (Venclexta) plus a hypomethylating agent (HMA) in induction-eligible acute myeloid leukemia (AML).
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
Advertisement
Advertisement